Xu H, Gouras G K, Greenfield J P, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic J N, Seeger M, Relkin N R, Liao F, Checler F, Buxbaum J D, Chait B T, Thinakaran G, Sisodia S S, Wang R, Greengard P, Gandy S
Laboratory of Molecular and Cellular Neuroscience, and Fisher Center for Research on Alzheimer Disease, The Rockefeller University, New York NY 10021, USA.
Nat Med. 1998 Apr;4(4):447-51. doi: 10.1038/nm0498-447.
Alzheimer's disease (AD) is characterized by the accumulation of cerebral plaques composed of 40- and 42-amino acid beta-amyloid (Abeta) peptides, and autosomal dominant forms of AD appear to cause disease by promoting brain Abeta accumulation. Recent studies indicate that postmenopausal estrogen replacement therapy may prevent or delay the onset of AD. Here we present evidence that physiological levels of 17beta-estradiol reduce the generation of Abeta by neuroblastoma cells and by primary cultures of rat, mouse and human embryonic cerebrocortical neurons. These results suggest a mechanism by which estrogen replacement therapy can delay or prevent AD.
阿尔茨海默病(AD)的特征是由40个和42个氨基酸的β-淀粉样蛋白(Aβ)肽组成的脑斑积累,而常染色体显性形式的AD似乎通过促进脑Aβ积累而致病。最近的研究表明,绝经后雌激素替代疗法可能预防或延缓AD的发病。在此我们提供证据表明,生理水平的17β-雌二醇可减少神经母细胞瘤细胞以及大鼠、小鼠和人类胚胎脑皮质神经元原代培养物中Aβ的生成。这些结果提示了雌激素替代疗法可以延缓或预防AD的一种机制。